PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION

New dietary treatment for epilepsy well tolerated and reduced seizures

Peer reviewed | Observational study & clinical feasibility trial | people

2021-07-23
(Press-News.org) The first clinical trial of a new dietary treatment for children and adults with severe forms of epilepsy, co-developed by UCL researchers and based on the ketogenic diet, has been successfully completed.

For the study, published in Brain Communications, clinicians evaluated the use of K.Vita®, (also known as Betashot), an oral liquid dietary supplement developed by UCL in collaboration with Royal Holloway, University of London, and Vitaflo International Ltd.

The ketogenic diet (KD) consists of high-fat, low-carbohydrate and adequate protein consumption and mimics the fasting state, altering the metabolism to use body fat as the primary fuel source. This switch from carbohydrates to fat for body fuel is known as ketosis.

It is widely used to treat drug resistant epilepsies. However, the highly restrictive diet, which can cause constipation, low blood sugar, and stomach problems, can have poor compliance and is not suitable for everyone. Some KD supplements are also known to be unappetising.

K.Vita is based on novel findings by UCL researchers*, who discovered a different underlying mechanism to explain why the KD is effective against epilepsy; in developing a new treatment, researchers also sought to reduce the adverse side effects caused by KD.

Corresponding author Professor Matthew Walker (UCL Queen Square Institute of Neurology) said: "The ketogenic diet has been used for 100 years to treat epilepsy, helping reduce seizures in both children and adults.

"It has long been thought the diet was effective due to its production of ketones**, however we now believe the increase in levels of the fatty acid, decanoic acid, also produced by the diet, may provide the powerful antiseizure effects.

"In this study we evaluated a newly developed medium chain triglyceride (type of dietary fat) supplement, designed to increase levels of decanoic acid, while also reducing the adverse side effects, and to be more palatable."

For the feasibility trial, researchers wanted to establish participants' tolerance (side effects such as bloating or cramps) to the treatment, acceptability (flavour, texture, taste) and compliance (how easy it is to use K.Vita at the advised quantity, as part of their daily diet).

As secondary outcomes, they also monitored the frequency of epileptic seizures or paroxysmal events (fits, attacks, convulsions) and whether ketone production was decreased.

In total, 35 children (aged 3 to 18) with genetically caused epilepsy and known to be unresponsive to drugs, and 26 adults with drug-resistant epilepsy*** (DRE), were given K.Vita liquid supplements (a drink), to be taken with meals. They were also asked to limit high-refined sugary food and beverages from their diets.

The trial lasted 12 weeks with K.Vita treatments increasing incrementally over time, taking into account individuals' tolerance to the treatment.

In total, 23/35 (66%) children and 18/26 (69%) adults completed the trial i.e they were continuing to take K.Vita at 12 weeks. Gastrointestinal disturbances were the primary reason for discontinuation, and their incidence decreased over time

Over three-quarters of participants/caregivers reported favourably on sensory attributes, such as taste, texture and appearance, and ease of use.

In regards to the secondary outcomes, there was a mean 50% reduction in seizures or paroxysmal events, and fewer than 10% of people on the diet produced significant ketones.

Commenting on the findings, Professor Walker, who is also a consultant neurologist at the National Hospital for Neurology and Neurosurgery, said: "Our study provides early evidence of the tolerability and effectiveness of a new dietary supplement in severe drug-resistant epilepsies in adults and children and provides a further treatment option in these devastating conditions.

"It also offers an alternative, more liberal, diet for those who cannot tolerate or do not have access to ketogenic diets."

He added: "While this study was not designed to include enough patients to fully assess the supplement's effects on seizures, it is exciting to report that there was a statistically significant reduction in the number of seizures in the group overall after three months of treatment.

"Furthermore, high ketone levels were not observed in over 90% of the participants. This indicates that the effect of the diet was independent from ketosis; this is important because high ketone levels in the ketogenic diets contribute to both short- and longer-term side effects."

First author, Dr Natasha Schoeler, Research Dietitian at UCL Great Ormond Street Institute of Child Health, commented: "This novel dietary approach for epilepsy management involves following the principles of a healthy balanced diet alongside use of K.Vita, allowing greater dietary freedom compared to ketogenic diets. Our approach also requires much less input from a specialist dietician than is required by traditional ketogenic diets, and so may allow more widespread access to people with drug-resistant epilepsy."

Researchers say larger, controlled studies of K.Vita are now needed to determine the precise epilepsies and conditions in which the supplement is most effective.

INFORMATION:

Patients were recruited from Great Ormond Street Hospital, Chalfont Centre for Epilepsy and The National Hospital for Neurology and Neuroscience, part of UCLH. The study was funded by VitaFlo International Ltd.

*It has been traditionally thought that the KD helps prevent seizures through the breakdown of fats, mimicking starvation. However, over the last decade, researchers at UCL and Royal Holloway, University of London, have shown that the fats themselves in the diet can prevent seizures. This has enabled the development of a novel dietary treatment for epilepsy that does not depend on a strict dietary regimen. Review published in Lancet Neurology

**Ketone is the chemical that your liver produces when it breaks down fats. The body uses ketones for energy typically during fasting, long periods of exercise, or when you don't have as many carbohydrates

*** Drug resistant epilepsy (DRE) is a term used to describe when adequate trials of two anti-epileptic drugs (AEDs) have failed to control a person's seizures. Some people also refer to this as "refractory", "intractable" or "uncontrolled" epilepsy.



ELSE PRESS RELEASES FROM THIS DATE:

Martian global dust storm ended winter early in the south

2021-07-23
A dust storm that engulfed Mars in 2018 destroyed a vortex of cold air around the planet's south pole and brought an early spring to the hemisphere. By contrast, the storm caused only minor distortions to the polar vortex in the northern hemisphere and no dramatic seasonal changes. Dr Paul Streeter of The Open University's Faculty of Science, Technology, Engineering and Mathematics will present the work today (23 July) at the virtual National Astronomy Meeting (NAM 2021). Over two weeks at the beginning of June 2018, localised dust storms combined and spread to form an impenetrable blanket of dust that hid almost the entire planet's surface. The global dust storm, ...

Studies find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa

Studies find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa
2021-07-23
CHAPEL HILL, North Carolina--Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective. The economic finding appeared July 22, 2021, in Lancet Global Health. The clinical trial results, reported May 19, 2021, in Lancet Global Health involved 37 people with diffuse large B-cell lymphoma (DLBCL). ...

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status
2021-07-23
CHAPEL HILL, North Carolina--A new study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions. This research, led by scientists at the University of North Carolina Lineberger Comprehensive Cancer Center, has important implications for patients who have not been offered immunotherapy because of their genetic profiles. The findings are published in the British Journal of Cancer. The National Cancer Institute estimates that 83,730 people in the United States will be diagnosed with bladder cancer in 2021, and the disease will cause 17,200 deaths. While the cancer ...

Mayo Clinic research suggests women over 65 be offered hereditary cancer genetic testing

2021-07-23
ROCHESTER, Minn. -- A new study by Fergus Couch, Ph.D., of Mayo Clinic Cancer Center, along with collaborators from the CARRIERS consortium, suggests that most women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing. The study was published Thursday, July 22, in the Journal of Clinical Oncology. Dr. Couch says that women over 65 rarely qualify for hereditary cancer genetic testing based on current testing guidelines because they are thought to exhibit low rates of genetic mutations in breast cancer genes. "Most studies of breast cancer genes have not looked at older women, those who were diagnosed over the age of 65," says Dr. Couch. He says these studies have mainly tested women with a strong family history of breast ...

Synlogic publishes papers in Nature journals demonstrating proof-of-mechanism and potential of synth

2021-07-22
- Data show dose-responsive, non-saturated increases in gastrointestinal consumption of Phe in humans by SYNB1618 - - SYNB1618 Phase 2 study in patients with PKU ongoing with proof-of-concept readout anticipated in 2H 2021 - - Phase 1 study of SYNB1934, an evolved strain of SYNB1618 in the PKU portfolio, initiated - CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the publication of two papers in the journals Nature Metabolism and Communications Biology. The publications detail findings ...

Study: Young workers now value respect over 'fun' perks in the workplace

2021-07-22
Millennials, often referred to as the "job-hopping generation," represent a group of young workers who once grabbed the national spotlight with their publicized demands for "fun" work perks, such as happy hours. However, researchers at the Novak Leadership Institute at the University of Missouri and Kansas State University discovered today's young workers -- ages 21-34 -- represent a life-stage shift toward placing more value on having respectful communication in the workplace over trendy work perks. "Millennials have been called the 'entitled generation,' and they kind of give young workers a bad rap because their often-publicized interests ...

Early-life social connections influence gene expression, stress resilience

Early-life social connections influence gene expression, stress resilience
2021-07-22
Having friends may not only be good for the health of your social life, but also for your actual health--if you're a hyena, that is. Strong social connections and greater maternal care early in life can influence molecular markers related to gene expression in DNA and future stress response, suggests a new University of Colorado Boulder study of spotted hyenas in the wild. Researchers found that more social connection and maternal care during a hyena's cub and subadult, or "teenage," years corresponded with lower adult stress hormone levels and fewer modifications to DNA, including near genes involved in immune function, inflammation and ...

'Good cholesterol' may protect liver

Good cholesterol may protect liver
2021-07-22
The body's so-called good cholesterol may be even better than we realize. New research from Washington University School of Medicine in St. Louis suggests that one type of high-density lipoprotein (HDL) has a previously unknown role in protecting the liver from injury. This HDL protects the liver by blocking inflammatory signals produced by common gut bacteria. The study is published July 23 in the journal Science. HDL is mostly known for mopping up cholesterol in the body and delivering it to the liver for disposal. But in the new study, the researchers identified a special type of HDL called HDL3 that, when produced by the intestine, blocks gut bacterial signals ...

Big data-derived tool facilitates closer monitoring of recovery from natural disasters

2021-07-22
By analyzing peoples' visitation patterns to essential establishments like pharmacies, religious centers and grocery stores during Hurricane Harvey, researchers at Texas A&M University have developed a framework to assess the recovery of communities after natural disasters in near real time. They said the information gleaned from their analysis would help federal agencies allocate resources equitably among communities ailing from a disaster. "Neighboring communities can be impacted very differently after a natural catastrophic event," said Dr. Ali Mostafavi, associate professor in the ...

Perfecting collagen production in osteogenesis imperfecta

Perfecting collagen production in osteogenesis imperfecta
2021-07-22
Most people can expect to break close to two bones in their lifetime, but those with osteogenesis imperfecta -- also known as brittle bone disease -- can break hundreds of bones before they even hit puberty. And while healthy bones can break from a hard fall or a bad car wreck, there may not be an apparent reason at all with brittle bone disease. Classified as a rare disease, osteogenesis imperfecta, or OI, affects 6-7 people out of every 100,000 live births and can range in severity depending on the specific mutation. And while there are currently few treatment options and no cure, ...

LAST 30 PRESS RELEASES:

Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[Press-News.org] New dietary treatment for epilepsy well tolerated and reduced seizures
Peer reviewed | Observational study & clinical feasibility trial | people